Loading
A phase 1/2 trial of 23ME-00610 in renal cell carcinoma, ovarian cancer, neuroendocrine tumours and small-cell lung cancer, run by 23andMe, Inc., active and no longer recruiting.
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT05199272 by 23andMe, Inc., with 141 participants enrolled, started 2021-12-29 and due to reach its primary completion in 2025-03. Interventions recorded: 23ME-00610.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Small-cell lung cancer, Ovarian cancer and the tag pipeline.
Shares Renal cell carcinoma, Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Ovarian cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/